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Protocol
========

1. Cell Staining
----------------

1.  Prepare the cells. The cells should be used while still actively growing (60- 80% confluence). Serum starve the cells overnight, plate them cells at 0.1 million per well in 0.5 mL serum-free medium in a 24-well plate and place in the incubator (37°C, 5% CO~2~) for 30 min - 2 hours to recover from trypsinization.

2.  Mix the primary and secondary antibodies. Mix (5 μL of primary anti-GLUT4 antibody with 1 μL secondary chicken anti-goat IgG antibody conjugated to AlexaFluor 488) x number of wells. Incubate for 10 minutes at room temperature, in the dark.

3.  Prepare a 2X working stock of insulin by diluting it in medium.

4.  Check if the cells have adhered or not.

5.  Gently add 6 μL antibody mix and 0.5 mL of your 2X working stock of insulin to the wells containing the cells. Avoid any turbulence of the medium. Incubate (37°C, 5% CO~2~) for 30 minutes, in the dark.

6.  Fix the cells by adding 0.5 mL of PBS + 1% PFA to each well, without shaking the cells. Incubate for 20 minutes at room temperature, in the dark.

7.  If your cells have adhered to the wells, gently lift them with a cell lifter. Transfer the cells (1 mL total) into tubes that fit in your flow cytometer and centrifuge to pellet the cells.

8.  Wash the pellet twice with 1 mL PBS and resuspend in 0.4 mL PBS + 1% PFA. At this point, cells can be wrapped in foil and stored in the fridge (4-8°C) or taken to the flow cytometer for immediate data acquisition.

2. Data Acquisition
-------------------

1.  Set a broad gate around the live cells in the side scatter (SSC) versus forward scatter (FCS) panel. Use a negative tube (cells not treated with insulin or cells \"stained\" with an isotype control) to set your FL1 parameter. Make sure your peak is completely in the panel, not cut on the lower side.

2.  Acquire data from at least 10,000 cells per tube.

3. Data Analysis
----------------

1.  Draw a gate around the live cells in the SSC vs FSC panel (Figure 1A). Plot the histograms of AlexaFluor 488 fluorescence intensity versus number of cells within the live-cell gate (Figure 1B). You can overlay different histograms to visualize differences but for quantitation, determine the mean and median fluorescence intensity for each cell population and use these numbers for your comparisons (Figure 1C).

2.  Normalize the data to the value obtained in the absence of insulin, as shown in Figures 1C and 1D.

4. Representative Results
-------------------------

In myoblasts isolated from a healthy individual (no insulin resistance), insulin induces a dose-dependent translocation of GLUT4 from the cytoplasm to the plasma membrane (Figure 1, left). In contrast, insulin does not induce GLUT4 translocation to the plasma membrane of myoblasts isolated from a patient with insulin resistance (Figure 1, right).

**Figure 1.** Example of a staining experiment. Myoblasts were isolated from a donor without insulin resistance (left) and from a patient with insulin resistance (right). **A**, SSC (side scatter) versus FCS (forward scatter) plot with a gate around the live cells. **B**, Cells gated in A, stained with the antibody against an external epitope of GLUT4, and left unstimulated (red) or stimulated with insulin 1 nM (blue), 10 nM (orange), or 100 nM (green). For figure clarity, we only show data without and with 100 nM insulin for the cells with insulin resistance. **C**, Mean fluorescence intensities (MFI) of the histograms shown in B were normalized to the MFI of the cells left unstimulated (no insulin). **D**, Plots of the normalized MFI data from the histograms shown in B.

Discussion
==========

We have demonstrated a rapid technique for quantifying the translocation of GLUT4 from the cytoplasm to the plasma membrane of cells by flow cytometry.

GLUT4 is only transiently expressed at the plasma membrane of cells and is endocytosed. Since the bound antibodies remain attached to the GLUT4, even during endocytosis, the fluorescence signal gives the total amount of GLUT4 that was exposed at the plasma membrane during the chosen duration of incubation in the presence of insulin.

This technique can also be applied to studying the translocation of other proteins from an intracellular compartment to the plasma membrane, provided a good antibody directed to an external epitope of the protein of interest is available. For example, a similar assay is now commonly used to assess the rate of degranulation of cytotoxic T lymphocytes and natural killer lymphocytes by measuring the translocation of CD107a to their plasma membrane^4,5^. The translocation of phosphatidylserine from the inner side of the plasma membrane to the outer side during cell apoptosis or necrosis can also be detected by flow cytometry, using fluorophore-labeled Annexin V^6^.

Besides rapidity of the assay, flow cytometry presents the advantage of allowing the study of protein translocation to the plasma membrane in mixed cell populations. Indeed, one can combine staining for cell subset markers and for the protein of interest, followed by data acquisition on a multi-laser flow cytometer^7^.

The amounts of antibodies given in paragraph 1.2 of the protocol are a starting point; we recommend you titrate your antibodies with your cells of interest to determine the minimum antibody concentration that gives you a maximum signal. A good starting range for the primary anti-human GLUT4 antibody we have used here would be 1-10 μL per tube (i.e. 0.2-2 μg antibody per tube), each tube containing no more than 1 million cells. For other primary antibodies, refer to the supplier\'s instructions.

Normalization of data is necessary as autofluorescence of cells will vary from donor to donor and from experiment to experiment.
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